Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). (Q39646903)
Jump to navigation
Jump to search
scientific article published on March 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). |
scientific article published on March 2012 |
Statements
1 reference
Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). (English)
1 reference
Michael W Stewart
1 reference
Philip J Rosenfeld
1 reference
Fernando M Penha
1 reference
Fenghua Wang
1 reference
Zohar Yehoshua
1 reference
Elena Bueno-Lopez
1 reference
Pedro F Lopez
1 reference
1 March 2012
1 reference
Identifiers
1 reference